In a randomized controlled trial (KCT0000939), desflurane was found to be beneficial to the immune response by maintaining the IL-2/IL-4 and CD4+/CD8+ T-cell ratios in breast cancer patients, providing an immune protective response.206. This evidence concerns the gene IL2 and breast carcinoma.